Akebia Therapeutics, Inc.
AKBA evidence brief
What we can confirm
- BioSniper Score:
- 4.4 / 10
- Market Cap:
- $268.6M
- Next Catalyst:
- Patent_Expiry · Jul 21, 2030
What it means
What to watch
Prepared research question
What matters most for AKBA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AKBA
Akebia Therapeutics is a fully integrated biopharmaceutical company focused on kidney disease, with two commercial products (Vafseo and Auryxia) and a pipeline of mid- and early-stage programs targeting rare kidney diseases and other indications.
Key risk: Generic competition for Auryxia
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 5 clinical trials · 2 catalysts for Akebia Therapeutics, Inc..
Akebia Therapeutics is a fully integrated biopharmaceutical company focused on kidney disease, with two commercial products (Vafseo and Auryxia) and a pipeline of mid- and early-stage programs targeting rare kidney diseases and other indications.
- Cash & equivalents of $155.5M as of 2026-06-30 [sec]
- Total revenue of $49.1M and net loss of -$8.9M for the six months ended 2026-06-30 [sec]
- Two commercial products: Vafseo (vadadustat) for anemia due to CKD and Auryxia (ferric citrate) for hyperphosphatemia [sec · filed 2026-04-28]
- Mid-stage pipeline includes praliciguat (Phase 2 for FSGS) and ebribafusp (Phase 2 for IgAN, C3G, LN) [sec_mda · as of 2026-08-05]
- Early-stage HIF molecules AKB-9090 (Phase 1 for CS-AKI) and AKB-10108 (preclinical for ROP) [sec_mda · as of 2026-08-05]
What works
- Two approved, revenue-generating products (Vafseo and Auryxia) provide a commercial foundation and net product revenue to support pipeline development [sec · filed 2026-04-28]
- Mid-stage rare kidney disease pipeline (praliciguat, ebribafusp) addresses areas of unmet need with Phase 2 trials underway [sec_mda · as of 2026-08-05]
- Early-stage HIF platform (AKB-9090, AKB-10108) offers potential expansion into acute kidney injury and other non-kidney indications [sec_mda · as of 2026-08-05]
- Cash position of $155.5M as of 2026-06-30 provides runway for ongoing R&D and commercial activities [sec]
What to weigh
- Net loss of -$8.9M for the six months ended 2026-06-30 indicates ongoing operating losses [sec]
- Shareholders' equity of $25.0M is relatively low compared to total debt of $52.4M as of 2026-06-30 [sec]
- Auryxia faces generic competition, which the company expects will adversely impact revenue [sec · filed 2026-04-28]
- Pipeline assets are early- to mid-stage; no late-stage pivotal programs beyond Vafseo and Auryxia are disclosed [sec_mda · as of 2026-08-05]
From the filings
Quoted directly from source documents.
Two commercial products for kidney disease
“We are a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease.”
SEC filings · April 28, 2026
Catalyst timeline
- 2030-07-21 · Patent_Expiry · FERRIC CITRATE — Patent expiry for Auryxia (ferric citrate) could open the door to additional generic competition.
- 2036-03-31 · Patent_Expiry · VADADUSTAT — Patent expiry for Vafseo (vadadustat) may eventually affect market exclusivity.
Risks & what to watch (4)›
Key risks
- Generic competition for Auryxia — Expects generic entry to adversely impact revenue [sec · filed 2026-04-28]
- Operating losses persist — Net loss of -$8.9M for six months ended 2026-06-30 [sec]
- Low equity relative to debt — Shareholders' equity $25.0M vs total debt $52.4M as of 2026-06-30 [sec]
- Pipeline stage risk — No late-stage pivotal programs beyond approved products; mid-stage trials are early [sec_mda · as of 2026-08-05]
What to watch
- Commercial performance of Vafseo and Auryxia, especially in light of generic competition for Auryxia [sec · filed 2026-04-28]
- Progress of Phase 2 trials for praliciguat (FSGS) and ebribafusp (IgAN, C3G, LN) [sec_mda · as of 2026-08-05]
- Phase 1 data for AKB-9090 in cardiac surgery-related acute kidney injury [sec_mda · as of 2026-08-05]
- Cash runway and ability to fund pipeline without further dilution or debt [sec]
Sources: SEC filings · SEC MD&A · Generated October 7, 2026 · How we verify sources →
Run Akebia Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Akebia Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 12.98 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
2 upcoming, next in ~1377d
0 buys · 1 sell (180d)
Catalysts
Regulatory
Financials
Short Interest
as of Apr 20, 2026- % of float
- 9.9%
- Days to cover
- 9.3
- Shares short
- 26,266,098
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
AKBA short interestGovernance
Frequently asked questions
What is the AI investment thesis for Akebia Therapeutics, Inc.?
Akebia Therapeutics is a fully integrated biopharmaceutical company focused on kidney disease, with two commercial products (Vafseo and Auryxia) and a pipeline of mid- and early-stage programs targeting rare kidney diseases and other indications.
What is Akebia Therapeutics, Inc.'s next catalyst?
Akebia Therapeutics, Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA205874" — expected July 21, 2030.
Who is the CEO of Akebia Therapeutics, Inc.?
Mr. John P. Butler MBA is the chief executive officer of Akebia Therapeutics, Inc. (AKBA).
Where is Akebia Therapeutics, Inc. headquartered?
Akebia Therapeutics, Inc. (AKBA) is headquartered in Cambridge, MA, United States.
What therapeutic areas does Akebia Therapeutics, Inc. focus on?
Akebia Therapeutics, Inc. develops therapies across Immunology, Dermatology, Hematology, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.